Log in

NASDAQ:NEOSNeos Therapeutics Stock Price, Forecast & News

$0.73
0.00 (0.00 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.71
Now: $0.73
$0.77
50-Day Range
$0.69
MA: $0.82
$1.00
52-Week Range
$0.60
Now: $0.73
$2.15
Volume81,857 shs
Average Volume191,551 shs
Market Capitalization$36.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.
Read More
Neos Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEOS
CUSIPN/A
Phone972-408-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.65 million
Book Value($0.26) per share

Profitability

Net Income$-16,900,000.00

Miscellaneous

Employees215
Market Cap$36.31 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive NEOS News and Ratings via Email

Sign-up to receive the latest news and ratings for NEOS and its competitors with MarketBeat's FREE daily newsletter.

Neos Therapeutics (NASDAQ:NEOS) Frequently Asked Questions

How has Neos Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NEOS shares have decreased by 47.1% and is now trading at $0.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Neos Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neos Therapeutics.

When is Neos Therapeutics' next earnings date?

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Neos Therapeutics.

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics Inc (NASDAQ:NEOS) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.06. The company had revenue of $14.49 million for the quarter. Neos Therapeutics had a negative net margin of 26.52% and a negative return on equity of 2,087.24%. View Neos Therapeutics' earnings history.

What price target have analysts set for NEOS?

2 brokers have issued twelve-month price targets for Neos Therapeutics' shares. Their forecasts range from $3.00 to $10.00. On average, they expect Neos Therapeutics' stock price to reach $6.50 in the next year. This suggests a possible upside of 790.4% from the stock's current price. View analysts' price targets for Neos Therapeutics.

Has Neos Therapeutics been receiving favorable news coverage?

News articles about NEOS stock have trended extremely negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neos Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutNeos Therapeutics.

Are investors shorting Neos Therapeutics?

Neos Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,110,000 shares, an increase of 6.6% from the April 30th total of 1,980,000 shares. Based on an average daily trading volume, of 247,700 shares, the short-interest ratio is presently 8.5 days. Approximately 4.3% of the shares of the company are sold short. View Neos Therapeutics' Current Options Chain.

Who are some of Neos Therapeutics' key competitors?

What other stocks do shareholders of Neos Therapeutics own?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the following people:
  • Mr. Richard I. Eisenstadt, CFO, Treasurer & Corp. Sec. (Age 61)
  • Mr. Gerald W. McLaughlin, CEO, Pres & Director (Age 51)
  • Mr. John P. Limongelli, Sr. VP & Gen. Counsel (Age 49)
  • Mr. Darren Heath, VP of Sales
  • Mr. Russ McMahen, Sr. VP of R&D

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering (IPO) on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Who are Neos Therapeutics' major shareholders?

Neos Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.43%), Sphera Funds Management LTD. (5.04%), Proxima Capital Management LLC (0.18%) and Wells Fargo & Company MN (0.17%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Gerald W Mclaughlin and Richard I Eisenstadt. View institutional ownership trends for Neos Therapeutics.

Which institutional investors are selling Neos Therapeutics stock?

NEOS stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Stonepine Capital Management LLC, and Proxima Capital Management LLC. View insider buying and selling activity for Neos Therapeutics.

Which institutional investors are buying Neos Therapeutics stock?

NEOS stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Gerald W Mclaughlin, and Richard I Eisenstadt. View insider buying and selling activity for Neos Therapeutics.

How do I buy shares of Neos Therapeutics?

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of NEOS stock can currently be purchased for approximately $0.73.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $36.31 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Neos Therapeutics employs 215 workers across the globe.

What is Neos Therapeutics' official website?

The official website for Neos Therapeutics is www.neostx.com.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.